05-06-2026 18:55 via medpagetoday.com

B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

(MedPage Today) -- The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, the global phase III MAJESTY trial showed.
By week 104, 37% of patients...
Read more »

Medical Industry news



ICE to No Longer Report Deaths of Detainees Recently Released From Custody
Aspirin and Bladder Cancer; Oncology Workforce Shortage; 'Exploding Immune Cells'
Novel Lupus Drugs Continue to Shine in Extended Early Data
Video: Police Tussle With Diabetes Experts at ADA Meeting
The World Cup Is Coming. Here’s What EDs Should Prepare For.
Ebola in Congo: What Happens When Global Response Capacity Disappears?
Politicization of Grants; Lessons From the 2014 Ebola Outbreak; Hantavirus Update
Deadly Cheese-Linked Outbreak; 15 Med Schools Probed; 'Concern' on FDA Voucher Pilot
New Change to PEPFAR Will Slash CDC's Presence Abroad
Brain Risks Tied to High Ultraprocessed Food Intake
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Tools to Fight Hantavirus Show Promise Despite Limited Funding
Spinal Cord Stimulation Restores Hand and Arm Mobility After Stroke
Private Health Insurance Doesn't Always Ensure Coverage, Survey Shows
Desktop versie